GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argenica Therapeutics Ltd (ASX:AGN) » Definitions » Other Current Receivables

Argenica Therapeutics (ASX:AGN) Other Current Receivables : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Argenica Therapeutics Other Current Receivables?

Argenica Therapeutics's Other Current Receivables for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Argenica Therapeutics's annual Other Current Receivables increased from Jun. 2022 (A$0.07 Mil) to Jun. 2023 (A$0.15 Mil) and increased from Jun. 2023 (A$0.15 Mil) to Jun. 2024 (A$0.37 Mil).


Argenica Therapeutics Other Current Receivables Historical Data

The historical data trend for Argenica Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argenica Therapeutics Other Current Receivables Chart

Argenica Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Other Current Receivables
0.08 0.07 0.15 0.37

Argenica Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Other Current Receivables Get a 7-Day Free Trial 0.07 - 0.15 - 0.37

Argenica Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


Argenica Therapeutics Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Argenica Therapeutics's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Argenica Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
117 Broadway, Unit 4, Nedlands, WA, AUS, 6009
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.

Argenica Therapeutics Headlines

No Headlines